ADC Landscape
GSK
BCMA · Multiple myeloma
ApprovedAntibody–Drug Conjugates
Target
BCMA
Payload
MMAF
Payload class
Auristatin
Linker
Non-cleavable (mc)
Indication
Multiple myeloma
Phase
Approved
Partner
— (Seagen tech)
Overview
First anti-BCMA ADC. Withdrawn in the US in 2022, then returned to approval on strong combination (DREAMM) data — a comeback story defined by managing ocular toxicity.
Technology
GSK works in Antibody–Drug Conjugates — A guided missile: an antibody that flies a chemo warhead straight to the tumor.
Read the Antibody–Drug Conjugates brief →Related companies
Daiichi Sankyo
HER2
Gilead
TROP2
AstraZeneca / Daiichi
TROP2
Pfizer (Seagen)
CD30
Pfizer (Seagen)
Nectin-4
Pfizer (Seagen)
Tissue Factor
Company website / source ↗ Open the interactive map →
◢ Boom-cycle briefing
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.